AnaptysBio to Participate in Upcoming Investor Conferences
November 05 2018 - 6:30AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on unmet medical needs in inflammation, today announced
that Hamza Suria, chief executive officer of AnaptysBio, will
present an overview of the company at the Jefferies 2018 London
Healthcare Conference on Thursday, November 15, 2018 at 10:40 a.m.
GMT.
A webcast of the Jefferies 2018 London Healthcare Conference
presentation will be available through the investor section of the
AnaptysBio website. A replay of the webcast will be available for
90 days following the event.
AnaptysBio will also participate in one-on-one investor meetings
at the 27th Annual Credit Suisse Healthcare Conference in
Scottsdale, Arizona on November 13, 2018.
About AnaptysBioAnaptysBio is a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on unmet medical needs in inflammation. The
company’s proprietary anti-inflammatory pipeline includes its
anti-IL-33 antibody (etokimab, previously referred to as ANB020)
for the treatment of moderate-to-severe atopic dermatitis, severe
eosinophilic asthma, and chronic rhinosinusitis with nasal polyps
(CRSwNP); its anti-IL-36R antibody (ANB019) for the treatment of
rare inflammatory diseases, including generalized pustular
psoriasis (GPP) and palmoplantar pustulosis (PPP), previously
referred to as palmo-plantar pustular psoriasis; and novel
anti-inflammatory checkpoint receptor modulator antibodies for
treatment of certain autoimmune diseases where immune checkpoint
receptors are insufficiently activated. AnaptysBio’s antibody
pipeline has been developed using its proprietary somatic
hypermutation (SHM) platform, which uses in vitro SHM for antibody
discovery and is designed to replicate key features of the human
immune system to overcome the limitations of competing antibody
discovery technologies. AnaptysBio has also developed multiple
therapeutic antibodies in an immuno-oncology partnership with
TESARO and an inflammation partnership with Celgene, including an
anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist
antibody (TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033),
which are currently under clinical development with TESARO, and an
anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the
clinic with Celgene.
Contact:Dominic Piscitelli
AnapytsBio,
Inc.858.362.6348dpiscitelli@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2023 to Apr 2024